MBX Biosciences, Inc. Additional Paid in Capital, Common Stock
MBX Biosciences, Inc. (MBX) had Additional Paid in Capital, Common Stock of $695.84 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-06
- 2026-06-30: Additional Paid in Capital, Common Stock $695.84M.
- 2026-03-31: Additional Paid in Capital, Common Stock $686.35M.
- 2025-12-31: Additional Paid in Capital, Common Stock $593.41M.
- 2025-09-30: Additional Paid in Capital, Common Stock $589.79M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $695.84M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $686.35M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $593.41M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $589.79M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $400.02M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $396.75M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $394.89M 10-K · filed 2026-03-12 |
| 2024-09-30 | $393.18M 10-Q · filed 2024-11-07 |
| 2023-12-31 | $3.05M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |